RANK/RANKL/OPG role in distraction osteogenesis

Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology and Endodontology

Volumn 109, Issue 5, 2010, Pages 679-686

  Pérez Sayáns, Mario ^a   Somoza Martín, José Manuel ^a   Barros Angueira, Francisco ^b   Rey, José Manuel Gándara ^a   García García, Abel ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^b Instituto de Salud Carlos III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TNFRSF11A PROTEIN, HUMAN;

BONE REGENERATION; BONE REMODELING; DISTRACTION OSTEOGENESIS; HUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PHYSIOLOGY; REVIEW; STROMA CELL;

BONE REGENERATION; BONE REMODELING; BONE RESORPTION; HUMANS; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS, DISTRACTION; OSTEOPROTEGERIN; RANK LIGAND; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; STROMAL CELLS;

EID: 77951253440     PISSN: 10792104     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tripleo.2009.10.042     Document Type: Review

References (66)

1. Codvilla A. On the jeans of lengthening in the lower limbs, the muscles and tissues which are shortened through deformity. Am J Orthop Surg 2 (1905) 353
2. Ilizarov G.A. Clinical application of the tension-stress effect for limb lengthening. Clin Orthop Relat Res 250 (1990) 8-26
3. Ilizarov G.A. The tension-stress effect on the genesis and growth of tissues: part II. The influence of the rate and frequency of distraction. Clin Orthop Relat Res 239 (1989) 263-285
4. Ilizarov G.A. The tension-stress effect on the genesis and growth of tissues: part I. The influence of stability of fixation and soft-tissue preservation. Clin Orthop Relat Res 238 (1989) 249-281
5. Karp N.S., McCarthy J.G., Schreiber J.S., Sissons H.A., and Thorne C.H. Membranous bone lengthening: a serial histological study. Ann Plast Surg 29 (1992) 2-7
6. McCarthy J.G., Schreiber J., Karp N., Thorne C.H., and Grayson B.H. Lengthening the human mandible by gradual distraction. Plast Reconstr Surg 89 (1992) 1-8 discussion 9-10
7. Block M.S., Almerico B., Crawford C., Gardiner D., and Chang A. Bone response to functioning implants in dog mandibular alveolar ridges augmented with distraction osteogenesis. Int J Oral Maxillofac Implants 13 (1998) 342-351
8. Toth B.A., Kim J.W., Chin M., and Cedars M. Distraction osteogenesis and its application to the midface and bony orbit in craniosynostosis syndromes. J Craniofac Surg 9 (1998) 100-113 discussion 119-22
9. Cano J., Campo J., Moreno L.A., and Bascones A. Osteogenic alveolar distraction: a review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 101 (2006) 11-28
10. Frankel V.H., Gold S., and Golyakhovsky V. The Ilizarov technique. Bull Hosp Joint Dis Orthop Inst 48 (1988) 17-27
11. Shevtsov V.I. Professor G. A. Ilizarov's contribution to the method of transosseous osteosynthesis. Bull Hosp Joint Dis 56 (1997) 11-15
12. Bouletreau P., and Longaker M.T. The molecular biology of distraction osteogenesis. Rev Stomatol Chir Maxillofac 105 (2004) 23-25
13. a Edición: 1998.
14. Neumann E. New pathophysological relevant metabolic pathways in osteoporosis. Future innovative therapies?. Z Rheumatol 65 (2006) 402-406
15. Rosa-Ranal M., de la Cruz D.A., Lorena-Rubio Y., and Larrea F. New paradigms in the regulation of bone metabolism. Rev Invest Clin 53 (2001) 362-369
16. Lemaire V., Tobin F.L., Greller L.D., Cho C.R., and Suva L.J. Modeling the interactions between osteoblast and osteoclast activities in bone remodeling. J Theor Biol 229 (2004) 293-309
17. Bar-Shavit Z. The osteoclast: a multinucleated, hematopoietic-origin, bone-resorbing osteoimmune cell. J Cell Biochem 102 (2007) 1130-1139
18. Blair H.C., and Athanasou N.A. Recent advances in osteoclast biology and pathological bone resorption. Histol Histopathol 19 (2004) 189-199
19. McCormick R.K. Osteoporosis: integrating biomarkers and other diagnostic correlates into the management of bone fragility. Altern Med Rev 12 (2007) 113-145
20. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 142 (2001) 5050-5055
21. Kawana F., and Sasaki T. Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice. J Electron Microsc 52 (2003) 515-525 (Tokyo)
22. Horowitz M.C., Xi Y., Wilson K., and Kacena M.A. Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. Cytokine Growth Factor Rev 12 (2001) 9-18
23. Boyce B.F., and Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther 9 Suppl 1 (2007) S1
24. Boyce B.F., and Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473 (2008 5/15) 139-146
25. Lerner U.H. New molecules in the tumor necrosis factor ligand and receptor superfamilies with importance for physiological and pathological bone resorption. Crit Rev Oral Biol Med 15 (2004) 64-81
26. Hofbauer L.C., Neubauer A., and Heufelder A.E. Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. Cancer 92 (2001) 460-470
27. Grimaud E., Soubigou L., Couillaud S., Coipeau P., Moreau A., Passuti N., et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am J Pathol 163 (2003) 2021-2031
28. Boyce B.F., and Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling. Arch Biochem Biophys 473 (2008) 139-146
29. Boyce B.F., and Xing L. The RANKL/RANK/OPG pathway. Curr Osteoporos Rep 5 (2007) 98-104
30. Rañal M.R., and de La Cruz D.A. Nuevos paradigmas en la regulación del metabolismo óseo. Rev Investig Clín 53 (2001) 362-369
31. Anderson D.M., Maraskovsky E., Billingsley W.L., Dougall W.C., Tometsko M.E., Roux E.R., et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 6656 (1997) 175-179
32. Hsu H., Lacey D.L., Dunstan C.R., Solovyev I., Colombero A., Timms E., et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96 (1999) 3540-3545
33. Vega D., Maalouf N.M., and Sakhaee K. The role of receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/osteoprotegerin: clinical implications. J Clin Endocrinol Metab 92 (2007) 4514-4521 Review
34. Esquivel Muñoz J.B., Chadid Nuñez G., Pereira Ebratt R., and Serrano Álvarez J.J. Estudio clínico controlado aleatorizado para evaluación del Emdogain como terapia adjunta en el tratamiento de recesiones gingivales. Univ Odontol 25 (2005) 4-11
35. Mizuno A., Amizuka N., Irie K., Murakami A., Fujise N., Kanno T., et al. Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin. Biochem Biophys Res Commun 247 (1998) 610-615
36. Schoppet M., Preissner K.T., and Hofbauer L.C. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol 22 (2002) 549-553
37. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
38. Wittrant Y., Theoleyre S., Couillaud S., Dunstan C., Heymann D., and Redini F. Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-kB ligand and osteoprotegerin biological activities. Exp Cell Res 293 (2004) 292-301
39. Boyle W.J., Simonet W.S., and Lacey D.L. Osteoclast differentiation and activation. Nature 423 6937 (2003) 337-342
40. Kong Y.Y., and Penninger J.M. Molecular control of bone remodeling and osteoporosis. Exp Gerontol 35 (2000) 947-956
41. American Society for Bone and Mineral Research. President′s Committee on nomenclature. J Bone Miner Res 15 (2000) 2293-2296
42. Kostenuik P.J., Bolon B., Morony S., Daris M., Geng Z., Carter C., et al. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 34 (2004) 656-664
43. Hofbauer L.C., Khosla S., Dunstan C.R., Lacey D.L., Boyle W.J., and Riggs B.L. The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption. J Bone Miner Res 15 (2000) 2-12
44. Nakamura H., Tsuji T., Hirata A., and Yamamoto T. Localization of osteoprotegerin (OPG) on bone surfaces and cement lines in rat tibia. J Histochem Cytochem 50 (2002) 945-953
45. Feige U. Osteoprotegerin. Ann Rheum Dis 60 Suppl 3 (2001) iii81-iii84
46. Einhorn T.A. The cell and molecular biology of fracture healing. Clin Orthop Relat Res 355 Suppl (1998) S7-S21
47. Nowazesh Ali M., Ejiri S., Kobayashi T., Anwar R.B., Oda K., Ohshima H., et al. Histologic study of the cellular events during rat mandibular distraction osteogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107 (2009) 325-335
48. Sato M., Yasui N., Nakase T., Kawahata H., Sugimoto M., Hirota S., et al. Expression of bone matrix proteins mRNA during distraction osteogenesis. J Bone Miner Res 13 (1998) 1221-1231
49. Kon T., Cho T.J., Aizawa T., Yamazaki M., Nooh N., Graves D., et al. Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. J Bone Miner Res 16 (2001) 1004-1014
50. Snyder C.C., Levine G.A., Swanson H.M., and Browne Jr. E.Z. Mandibular lengthening by gradual distraction. Preliminary report. Plast Reconstr Surg 51 (1973) 506-508
51. Mehrara B.J., Rowe N.M., Steinbrech D.S., Dudziak M.E., Saadeh P.B., McCarthy J.G., et al. Rat mandibular distraction osteogenesis: II. Molecular analysis of transforming growth factor beta-1 and osteocalcin gene expression. Plast Reconstr Surg 103 (1999) 536-547
52. Bouletreau P.J., Warren S.M., and Longaker M.T. The molecular biology of distraction osteogenesis. J Craniomaxillofac Surg 30 (2002) 1-11
53. Pacicca D.M., Patel N., Lee C., Salisbury K., Lehmann W., Carvalho R., et al. Expression of angiogenic factors during distraction osteogenesis. Bone 33 (2003) 889-898
54. Ai-Aql Z.S., Alagl A.S., Graves D.T., Gerstenfeld L.C., and Einhorn T.A. Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis. J Dent Res 87 (2008) 107-118
55. Zhu W.Q., Wang X., Wang X.X., and Wang Z.Y. Molecular mechanism of bone remodelling during mandibular distraction osteogenesis in rats. Zhonghua Kou Qiang Yi Xue Za Zhi 42 (2007) 729-732
56. Lewinson D., Rachmiel A., Rihani-Bisharat S., Kraiem Z., Schenzer P., Korem S., et al. Stimulation of Fos- and Jun-related genes during distraction osteogenesis. J Histochem Cytochem 51 (2003) 1161-1168
57. Zhu W.Q., Wang X., Wang X.X., and Wang Z.Y. Temporal and spatial expression of osteoprotegerin and receptor activator of nuclear factor -kappaB ligand during mandibular distraction in rats. J Craniomaxillofac Surg 35 (2007) 103-111
58. Flick L.M., Weaver J.M., Ulrich-Vinther M., Abuzzahab F., Zhang X., Dougall W.C., et al. Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. J Orthop Res 21 (2003) 676-684
59. Crotti T.N., Smith M.D., Findlay D.M., Zreiqat H., Ahern M.J., Weedon H., et al. Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin. Bsiomaterials 25 (2004) 565-573
60. Ulrich-Vinther M., Carmody E.E., Goater J.J., S balle K., O'Keefe R.J., and Schwarz E.M. Recombinant adeno-associated virus-mediated osteoprotegerin gene therapy inhibits wear debris-induced osteolysis. J Bone Joint Surg Am 84 A (2002) 1405-1412
61. Silvestrini G., Ballanti P., Patacchioli F., Leopizzi M., Gualtieri N., Monnazzi P., et al. Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat. J Mol Histol 36 (2005) 59-67
62. Zauli G., Melloni E., Capitani S., and Secchiero P. Role of full-length osteoprotegerin in tumor cell biology. Cell Mol Life Sci 66 (2009) 841-851
63. Kong Y.Y., Yoshida H., Sarosi I., Tan H.L., Timms E., Capparelli C., et al. OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature 397 6717 (1999) 315-323
64. Hofbauer L.C., and Schoppet M. Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292 (2004) 490-495
65. Onyia J.E., Galvin R.J., Ma Y.L., Halladay D.L., Miles R.R., Yang X., et al. Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. J Pharmacol Exp Ther 309 (2004) 369-379
66. Ali M.N., Ejiri S., Kobayashi T., Anwar R.B., Oda K., Ohshima H., et al. Histologic study of the cellular events during rat mandibular distraction osteogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 107 (2009) 325-335